Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm
Aim To retrospectively evaluate the outcomes of conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) ≥10 cm. Methods Twenty‐five patients with naïve HCC ≥10 cm (mean maximum tumor diameter, 130 ± 27.6 mm; single [n = 12], 2–9 [n = 6], and ≥10 [n = 7]) without extra...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2019-07, Vol.49 (7), p.787-798 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 798 |
|---|---|
| container_issue | 7 |
| container_start_page | 787 |
| container_title | Hepatology research |
| container_volume | 49 |
| creator | Miyayama, Shiro Kikuchi, Yuzo Yoshida, Masanori Yamashiro, Masashi Sugimori, Natsuki Ikeda, Rie Okimura, Kotaro Sakuragawa, Naoko Ueda, Teruyuki Sanada, Taku Watanabe, Hiroyuki Notsumata, Kazuo |
| description | Aim
To retrospectively evaluate the outcomes of conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) ≥10 cm.
Methods
Twenty‐five patients with naïve HCC ≥10 cm (mean maximum tumor diameter, 130 ± 27.6 mm; single [n = 12], 2–9 [n = 6], and ≥10 [n = 7]) without extrahepatic spread treated with cTACE were eligible. Five (20%) had vascular invasion. Two to three stepwise cTACE sessions using iodized oil ≤10 mL in one cTACE session were scheduled. When the tumor recurred, additional cTACE was repeated on demand, if possible. Overall survival (OS) rates were calculated using the Kaplan–Meier method. The prognostic factors were evaluated using uni‐ and multivariate analyses.
Results
Stepwise cTACE sessions were completed for 20 (80%) patients, but could not be completed for four (16%). In the remaining (4%) patient, the whole tumor was embolized in one session. Additional treatment, mainly cTACE, was undertaken for 19 (76%) patients. The OS rates at 1, 3, and 5 years were 68, 34.7, and 23.1%, respectively. A tumor number of three was a significant prognostic factor (P = 0.020) and the 1‐, 3‐, and 4‐year OS rates in patients with ≤3 and ≥4 tumors were 81.3 and 33.3, 55.6 and 11.1, and 38.9% and 0%, respectively. Whole tumor embolization and the serum level of protein induced by vitamin K absence or antagonist‐II were also significant prognostic factors (P |
| doi_str_mv | 10.1111/hepr.13335 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2197323595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2262650630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4475-9eba1d61ceb9bc7f74de3fd9c536cd324dd63cee99d274462a9b883ce3928f0e3</originalsourceid><addsrcrecordid>eNp90M9KwzAcB_AgipvTiw8gBS8idOZf0-YoYzphMBEFT5Y0_ZV1tM1MWmW-gQ_ii_kkZm568GAu-cOHb5IvQscED4kfF3NY2iFhjEU7qE-SmIaY8cddv2aJCAXjoocOnFtgTGJM-T7qMSxxzEXSR0-zrtWmBheYItCmeYGmLU2jqqC1qnHKtmBLv9NzqA3UmanKN7UWQWFs4G9WrdFQVV2lbKCV1WVjahV8vn8QHOj6EO0VqnJwtJ0H6OFqfD-ahNPZ9c3ochpqzuMolJApkguiIZOZjouY58CKXOqICZ0zyvNcMA0gZU5jzgVVMksSf8IkTQoMbIDONrlLa547cG1al279LtWA6VxKiYwZZZGMPD39Qxems_7HXlFBRYQFw16db5S2xjkLRbq0Za3sKiU4XbeerltPv1v3-GQb2WU15L_0p2YPyAa8lhWs_olKJ-Pbu03oF7rVj10</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2262650630</pqid></control><display><type>article</type><title>Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Miyayama, Shiro ; Kikuchi, Yuzo ; Yoshida, Masanori ; Yamashiro, Masashi ; Sugimori, Natsuki ; Ikeda, Rie ; Okimura, Kotaro ; Sakuragawa, Naoko ; Ueda, Teruyuki ; Sanada, Taku ; Watanabe, Hiroyuki ; Notsumata, Kazuo</creator><creatorcontrib>Miyayama, Shiro ; Kikuchi, Yuzo ; Yoshida, Masanori ; Yamashiro, Masashi ; Sugimori, Natsuki ; Ikeda, Rie ; Okimura, Kotaro ; Sakuragawa, Naoko ; Ueda, Teruyuki ; Sanada, Taku ; Watanabe, Hiroyuki ; Notsumata, Kazuo</creatorcontrib><description>Aim
To retrospectively evaluate the outcomes of conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) ≥10 cm.
Methods
Twenty‐five patients with naïve HCC ≥10 cm (mean maximum tumor diameter, 130 ± 27.6 mm; single [n = 12], 2–9 [n = 6], and ≥10 [n = 7]) without extrahepatic spread treated with cTACE were eligible. Five (20%) had vascular invasion. Two to three stepwise cTACE sessions using iodized oil ≤10 mL in one cTACE session were scheduled. When the tumor recurred, additional cTACE was repeated on demand, if possible. Overall survival (OS) rates were calculated using the Kaplan–Meier method. The prognostic factors were evaluated using uni‐ and multivariate analyses.
Results
Stepwise cTACE sessions were completed for 20 (80%) patients, but could not be completed for four (16%). In the remaining (4%) patient, the whole tumor was embolized in one session. Additional treatment, mainly cTACE, was undertaken for 19 (76%) patients. The OS rates at 1, 3, and 5 years were 68, 34.7, and 23.1%, respectively. A tumor number of three was a significant prognostic factor (P = 0.020) and the 1‐, 3‐, and 4‐year OS rates in patients with ≤3 and ≥4 tumors were 81.3 and 33.3, 55.6 and 11.1, and 38.9% and 0%, respectively. Whole tumor embolization and the serum level of protein induced by vitamin K absence or antagonist‐II were also significant prognostic factors (P < 0.001 and P = 0.042, respectively). Bile duct complications requiring additional interventions developed in two (8%) patients.
Conclusion
Conventional TACE is safe and effective for huge HCCs, but has limited effects in cases with four or more tumors.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13335</identifier><identifier>PMID: 30907468</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Bile ducts ; conventional transarterial chemoembolization ; Embolization ; Hepatocellular carcinoma ; huge hepatocellular carcinoma ; Liver cancer ; Medical prognosis ; prognosis ; Tumors ; Vitamin K</subject><ispartof>Hepatology research, 2019-07, Vol.49 (7), p.787-798</ispartof><rights>2019 The Japan Society of Hepatology</rights><rights>2019 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4475-9eba1d61ceb9bc7f74de3fd9c536cd324dd63cee99d274462a9b883ce3928f0e3</citedby><cites>FETCH-LOGICAL-c4475-9eba1d61ceb9bc7f74de3fd9c536cd324dd63cee99d274462a9b883ce3928f0e3</cites><orcidid>0000-0001-6119-5874</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13335$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13335$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30907468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyayama, Shiro</creatorcontrib><creatorcontrib>Kikuchi, Yuzo</creatorcontrib><creatorcontrib>Yoshida, Masanori</creatorcontrib><creatorcontrib>Yamashiro, Masashi</creatorcontrib><creatorcontrib>Sugimori, Natsuki</creatorcontrib><creatorcontrib>Ikeda, Rie</creatorcontrib><creatorcontrib>Okimura, Kotaro</creatorcontrib><creatorcontrib>Sakuragawa, Naoko</creatorcontrib><creatorcontrib>Ueda, Teruyuki</creatorcontrib><creatorcontrib>Sanada, Taku</creatorcontrib><creatorcontrib>Watanabe, Hiroyuki</creatorcontrib><creatorcontrib>Notsumata, Kazuo</creatorcontrib><title>Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim
To retrospectively evaluate the outcomes of conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) ≥10 cm.
Methods
Twenty‐five patients with naïve HCC ≥10 cm (mean maximum tumor diameter, 130 ± 27.6 mm; single [n = 12], 2–9 [n = 6], and ≥10 [n = 7]) without extrahepatic spread treated with cTACE were eligible. Five (20%) had vascular invasion. Two to three stepwise cTACE sessions using iodized oil ≤10 mL in one cTACE session were scheduled. When the tumor recurred, additional cTACE was repeated on demand, if possible. Overall survival (OS) rates were calculated using the Kaplan–Meier method. The prognostic factors were evaluated using uni‐ and multivariate analyses.
Results
Stepwise cTACE sessions were completed for 20 (80%) patients, but could not be completed for four (16%). In the remaining (4%) patient, the whole tumor was embolized in one session. Additional treatment, mainly cTACE, was undertaken for 19 (76%) patients. The OS rates at 1, 3, and 5 years were 68, 34.7, and 23.1%, respectively. A tumor number of three was a significant prognostic factor (P = 0.020) and the 1‐, 3‐, and 4‐year OS rates in patients with ≤3 and ≥4 tumors were 81.3 and 33.3, 55.6 and 11.1, and 38.9% and 0%, respectively. Whole tumor embolization and the serum level of protein induced by vitamin K absence or antagonist‐II were also significant prognostic factors (P < 0.001 and P = 0.042, respectively). Bile duct complications requiring additional interventions developed in two (8%) patients.
Conclusion
Conventional TACE is safe and effective for huge HCCs, but has limited effects in cases with four or more tumors.</description><subject>Bile ducts</subject><subject>conventional transarterial chemoembolization</subject><subject>Embolization</subject><subject>Hepatocellular carcinoma</subject><subject>huge hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>prognosis</subject><subject>Tumors</subject><subject>Vitamin K</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp90M9KwzAcB_AgipvTiw8gBS8idOZf0-YoYzphMBEFT5Y0_ZV1tM1MWmW-gQ_ii_kkZm568GAu-cOHb5IvQscED4kfF3NY2iFhjEU7qE-SmIaY8cddv2aJCAXjoocOnFtgTGJM-T7qMSxxzEXSR0-zrtWmBheYItCmeYGmLU2jqqC1qnHKtmBLv9NzqA3UmanKN7UWQWFs4G9WrdFQVV2lbKCV1WVjahV8vn8QHOj6EO0VqnJwtJ0H6OFqfD-ahNPZ9c3ochpqzuMolJApkguiIZOZjouY58CKXOqICZ0zyvNcMA0gZU5jzgVVMksSf8IkTQoMbIDONrlLa547cG1al279LtWA6VxKiYwZZZGMPD39Qxems_7HXlFBRYQFw16db5S2xjkLRbq0Za3sKiU4XbeerltPv1v3-GQb2WU15L_0p2YPyAa8lhWs_olKJ-Pbu03oF7rVj10</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Miyayama, Shiro</creator><creator>Kikuchi, Yuzo</creator><creator>Yoshida, Masanori</creator><creator>Yamashiro, Masashi</creator><creator>Sugimori, Natsuki</creator><creator>Ikeda, Rie</creator><creator>Okimura, Kotaro</creator><creator>Sakuragawa, Naoko</creator><creator>Ueda, Teruyuki</creator><creator>Sanada, Taku</creator><creator>Watanabe, Hiroyuki</creator><creator>Notsumata, Kazuo</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6119-5874</orcidid></search><sort><creationdate>201907</creationdate><title>Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm</title><author>Miyayama, Shiro ; Kikuchi, Yuzo ; Yoshida, Masanori ; Yamashiro, Masashi ; Sugimori, Natsuki ; Ikeda, Rie ; Okimura, Kotaro ; Sakuragawa, Naoko ; Ueda, Teruyuki ; Sanada, Taku ; Watanabe, Hiroyuki ; Notsumata, Kazuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4475-9eba1d61ceb9bc7f74de3fd9c536cd324dd63cee99d274462a9b883ce3928f0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bile ducts</topic><topic>conventional transarterial chemoembolization</topic><topic>Embolization</topic><topic>Hepatocellular carcinoma</topic><topic>huge hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>prognosis</topic><topic>Tumors</topic><topic>Vitamin K</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyayama, Shiro</creatorcontrib><creatorcontrib>Kikuchi, Yuzo</creatorcontrib><creatorcontrib>Yoshida, Masanori</creatorcontrib><creatorcontrib>Yamashiro, Masashi</creatorcontrib><creatorcontrib>Sugimori, Natsuki</creatorcontrib><creatorcontrib>Ikeda, Rie</creatorcontrib><creatorcontrib>Okimura, Kotaro</creatorcontrib><creatorcontrib>Sakuragawa, Naoko</creatorcontrib><creatorcontrib>Ueda, Teruyuki</creatorcontrib><creatorcontrib>Sanada, Taku</creatorcontrib><creatorcontrib>Watanabe, Hiroyuki</creatorcontrib><creatorcontrib>Notsumata, Kazuo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyayama, Shiro</au><au>Kikuchi, Yuzo</au><au>Yoshida, Masanori</au><au>Yamashiro, Masashi</au><au>Sugimori, Natsuki</au><au>Ikeda, Rie</au><au>Okimura, Kotaro</au><au>Sakuragawa, Naoko</au><au>Ueda, Teruyuki</au><au>Sanada, Taku</au><au>Watanabe, Hiroyuki</au><au>Notsumata, Kazuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2019-07</date><risdate>2019</risdate><volume>49</volume><issue>7</issue><spage>787</spage><epage>798</epage><pages>787-798</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
To retrospectively evaluate the outcomes of conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) ≥10 cm.
Methods
Twenty‐five patients with naïve HCC ≥10 cm (mean maximum tumor diameter, 130 ± 27.6 mm; single [n = 12], 2–9 [n = 6], and ≥10 [n = 7]) without extrahepatic spread treated with cTACE were eligible. Five (20%) had vascular invasion. Two to three stepwise cTACE sessions using iodized oil ≤10 mL in one cTACE session were scheduled. When the tumor recurred, additional cTACE was repeated on demand, if possible. Overall survival (OS) rates were calculated using the Kaplan–Meier method. The prognostic factors were evaluated using uni‐ and multivariate analyses.
Results
Stepwise cTACE sessions were completed for 20 (80%) patients, but could not be completed for four (16%). In the remaining (4%) patient, the whole tumor was embolized in one session. Additional treatment, mainly cTACE, was undertaken for 19 (76%) patients. The OS rates at 1, 3, and 5 years were 68, 34.7, and 23.1%, respectively. A tumor number of three was a significant prognostic factor (P = 0.020) and the 1‐, 3‐, and 4‐year OS rates in patients with ≤3 and ≥4 tumors were 81.3 and 33.3, 55.6 and 11.1, and 38.9% and 0%, respectively. Whole tumor embolization and the serum level of protein induced by vitamin K absence or antagonist‐II were also significant prognostic factors (P < 0.001 and P = 0.042, respectively). Bile duct complications requiring additional interventions developed in two (8%) patients.
Conclusion
Conventional TACE is safe and effective for huge HCCs, but has limited effects in cases with four or more tumors.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30907468</pmid><doi>10.1111/hepr.13335</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6119-5874</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2019-07, Vol.49 (7), p.787-798 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2197323595 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Bile ducts conventional transarterial chemoembolization Embolization Hepatocellular carcinoma huge hepatocellular carcinoma Liver cancer Medical prognosis prognosis Tumors Vitamin K |
| title | Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T11%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20conventional%20transarterial%20chemoembolization%20for%20hepatocellular%20carcinoma%20%E2%89%A510%20cm&rft.jtitle=Hepatology%20research&rft.au=Miyayama,%20Shiro&rft.date=2019-07&rft.volume=49&rft.issue=7&rft.spage=787&rft.epage=798&rft.pages=787-798&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13335&rft_dat=%3Cproquest_cross%3E2262650630%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2262650630&rft_id=info:pmid/30907468&rfr_iscdi=true |